Company Information

Company BioMerieux
www.biomerieux.com
Type:
Company
Country:
France
Sector:
Pharmaceuticals & Biotechnology
Ownership:
Publicly Listed
Global Compact Status:
Active
Participant Since
18 June 2003
Next Communication on Progress (COP) due on:
31 December 2023

Financial Information


Twitter Feed from BioMerieux

Communication On Progress

Published On Title Level/Status
2022-11-24 Communication on Progress 2021 Active
2021-11-18 bioMerieux Communication on Progress 2020 Active
2020-07-30 bioMérieux Communication on Progress 2019 Active
2019-12-06 Communication sur le Progrès 2018 Active
2019-12-06 Communication on Progress 2018 Active
2018-12-04 Communication on Progress Active
2017-12-04 Communication on Progress Active
2016-07-22 2015 - bioMerieux Communication on Progress Active
2016-03-11 bioMérieux Communication on Progress Active
2014-12-10 Communication on Progress Active
2014-01-10 2012 Communication on Progress Active
2012-07-13 Communication on Progress Active
2011-06-17 2011 Communication on Progress Learner
2010-06-15 2010 Communication on Progress Not applicable
2009-05-07 bioMerieux Good Practice 2007-2008 Not applicable
2009-03-10 Grace Period Letter Not applicable
2008-02-08 Actions to support and protect access to healthcare in Southeast Asia in the aftermath of the tsunami Not applicable
2007-02-07 Initiatives to improve research on emerging infectious pathogens and facilitate access to healthcare for all throughout the world (p.30 at link below) Not applicable
2005-07-13 Initiatives Undertaken to Improve Energy and Natural Resource Management at bioMérieux Not applicable

Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.

Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP, for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.